Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions

Michael Eden; Samantha Harrison; Michelle Griffin; Mats Lambe; David Pettersson; Anna Gavin; David H. Brewster; Yulan Lin; Tom B. Johannesen; Roger L. Milne; Helen Farrugia; Diane Nishri; Mary Jane King; Dyfed W. Huws; Janet Warlow; Donna Turner; Craig C. Earle; Mick Peake; Jem Rashbass

doi:10.1016/j.canep.2018.10.019

Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions

Michael Eden^*, Samantha Harrison, Michelle Griffin, Mats Lambe, David Pettersson, Anna Gavin, David H. Brewster, Yulan Lin, Tom B. Johannesen, Roger L. Milne, Helen Farrugia, Diane Nishri, Mary Jane King, Dyfed W. Huws, Janet Warlow, Donna Turner, Craig C. Earle, Mick Peake, Jem Rashbass

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

20 Citations (Scopus)

Abstract

Background: International cancer survival comparisons use cancer registration data to report cancer survival, which informs the development of cancer policy and practice. Studies like the International Cancer Benchmarking Partnership (ICBP) have a duty to understand how registration differences impact on survival prior to drawing conclusions. Methods: Key informants reported differences in registration practice for capturing incidence date, death certificate case handling and registration of multiple primary tumours. Sensitivity analyses estimated their impact on one-year survival using baseline and supplementary cancer registration data from England and Sweden. Results: Variations in registration practice accounted for up to a 7.3 percentage point difference between unadjusted (estimates from previous ICBP survival data) and adjusted (estimates recalculated accounting for registration differences) one-year survival, depending on tumour site and jurisdiction. One-year survival estimates for four jurisdictions were affected by adjustment: New South Wales, Norway, Ontario, Sweden. Sweden and Ontario's survival reduced after adjustment, yet they remained the jurisdictions with the highest survival for breast and ovarian cancer respectively. Sweden had the highest unadjusted lung cancer survival of 43.6% which was adjusted to 39.0% leaving Victoria and Manitoba with the highest estimate at 42.7%. For colorectal cancer, Victoria's highest survival of 85.1% remained unchanged after adjustment. Conclusion: Population-based cancer survival comparisons can be subject to registration biases that may impact the reported 'survival gap’ between populations. Efforts should be made to apply consistent registration practices internationally. In the meantime, survival comparison studies should provide acknowledgement of or adjustment for the registration biases that may affect their conclusions.

Original language	English
Pages (from-to)	184-192
Number of pages	9
Journal	Cancer Epidemiology
Volume	58
DOIs	https://doi.org/10.1016/j.canep.2018.10.019
Publication status	Published - Feb 2019

Bibliographical note

Funding Information:
This study was supported primarily by NHS England , with additional contributions from Cancer Control Alberta , Cancer Institute NSW , Norwegian Directorate of Health , Cancer Care Ontario , Scottish Government , Cancer Council Victoria , Public Health Wales , Northern Ireland Cancer Registry , Public Health Agency for Northern Ireland , Tenovus Cancer Care , and Danish Cancer Society . Funders had no involvement in the study design, data collection, analysis and interpretation of data, in the writing of the report; or in the decision to submit the article for publication.

Publisher Copyright:
© 2018

Keywords

Cancer registration
Cancer survival
Date of diagnosis
Death certificate
International comparisons
Multiple primaries

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.canep.2018.10.019

Cite this

Eden, M., Harrison, S., Griffin, M., Lambe, M., Pettersson, D., Gavin, A., Brewster, D. H., Lin, Y., Johannesen, T. B., Milne, R. L., Farrugia, H., Nishri, D., King, M. J., Huws, D. W., Warlow, J., Turner, D., Earle, C. C., Peake, M., & Rashbass, J. (2019). Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions. Cancer Epidemiology, 58, 184-192. https://doi.org/10.1016/j.canep.2018.10.019

@article{90df245e9e4e46f898b603765b9055cc,

title = "Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions",

abstract = "Background: International cancer survival comparisons use cancer registration data to report cancer survival, which informs the development of cancer policy and practice. Studies like the International Cancer Benchmarking Partnership (ICBP) have a duty to understand how registration differences impact on survival prior to drawing conclusions. Methods: Key informants reported differences in registration practice for capturing incidence date, death certificate case handling and registration of multiple primary tumours. Sensitivity analyses estimated their impact on one-year survival using baseline and supplementary cancer registration data from England and Sweden. Results: Variations in registration practice accounted for up to a 7.3 percentage point difference between unadjusted (estimates from previous ICBP survival data) and adjusted (estimates recalculated accounting for registration differences) one-year survival, depending on tumour site and jurisdiction. One-year survival estimates for four jurisdictions were affected by adjustment: New South Wales, Norway, Ontario, Sweden. Sweden and Ontario's survival reduced after adjustment, yet they remained the jurisdictions with the highest survival for breast and ovarian cancer respectively. Sweden had the highest unadjusted lung cancer survival of 43.6% which was adjusted to 39.0% leaving Victoria and Manitoba with the highest estimate at 42.7%. For colorectal cancer, Victoria's highest survival of 85.1% remained unchanged after adjustment. Conclusion: Population-based cancer survival comparisons can be subject to registration biases that may impact the reported 'survival gap{\textquoteright} between populations. Efforts should be made to apply consistent registration practices internationally. In the meantime, survival comparison studies should provide acknowledgement of or adjustment for the registration biases that may affect their conclusions.",

keywords = "Cancer registration, Cancer survival, Date of diagnosis, Death certificate, International comparisons, Multiple primaries",

author = "Michael Eden and Samantha Harrison and Michelle Griffin and Mats Lambe and David Pettersson and Anna Gavin and Brewster, {David H.} and Yulan Lin and Johannesen, {Tom B.} and Milne, {Roger L.} and Helen Farrugia and Diane Nishri and King, {Mary Jane} and Huws, {Dyfed W.} and Janet Warlow and Donna Turner and Earle, {Craig C.} and Mick Peake and Jem Rashbass",

note = "Funding Information: This study was supported primarily by NHS England , with additional contributions from Cancer Control Alberta , Cancer Institute NSW , Norwegian Directorate of Health , Cancer Care Ontario , Scottish Government , Cancer Council Victoria , Public Health Wales , Northern Ireland Cancer Registry , Public Health Agency for Northern Ireland , Tenovus Cancer Care , and Danish Cancer Society . Funders had no involvement in the study design, data collection, analysis and interpretation of data, in the writing of the report; or in the decision to submit the article for publication. Publisher Copyright: {\textcopyright} 2018",

year = "2019",

month = feb,

doi = "10.1016/j.canep.2018.10.019",

language = "English",

volume = "58",

pages = "184--192",

journal = "Cancer Epidemiology",

issn = "1877-7821",

publisher = "Elsevier Ltd.",

}

Eden, M, Harrison, S, Griffin, M, Lambe, M, Pettersson, D, Gavin, A, Brewster, DH, Lin, Y, Johannesen, TB, Milne, RL, Farrugia, H, Nishri, D, King, MJ, Huws, DW, Warlow, J, Turner, D, Earle, CC, Peake, M & Rashbass, J 2019, 'Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions', Cancer Epidemiology, vol. 58, pp. 184-192. https://doi.org/10.1016/j.canep.2018.10.019

TY - JOUR

T1 - Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions

AU - Eden, Michael

AU - Harrison, Samantha

AU - Griffin, Michelle

AU - Lambe, Mats

AU - Pettersson, David

AU - Gavin, Anna

AU - Brewster, David H.

AU - Lin, Yulan

AU - Johannesen, Tom B.

AU - Milne, Roger L.

AU - Farrugia, Helen

AU - Nishri, Diane

AU - King, Mary Jane

AU - Huws, Dyfed W.

AU - Warlow, Janet

AU - Turner, Donna

AU - Earle, Craig C.

AU - Peake, Mick

AU - Rashbass, Jem

N1 - Funding Information: This study was supported primarily by NHS England , with additional contributions from Cancer Control Alberta , Cancer Institute NSW , Norwegian Directorate of Health , Cancer Care Ontario , Scottish Government , Cancer Council Victoria , Public Health Wales , Northern Ireland Cancer Registry , Public Health Agency for Northern Ireland , Tenovus Cancer Care , and Danish Cancer Society . Funders had no involvement in the study design, data collection, analysis and interpretation of data, in the writing of the report; or in the decision to submit the article for publication. Publisher Copyright: © 2018

PY - 2019/2

Y1 - 2019/2

N2 - Background: International cancer survival comparisons use cancer registration data to report cancer survival, which informs the development of cancer policy and practice. Studies like the International Cancer Benchmarking Partnership (ICBP) have a duty to understand how registration differences impact on survival prior to drawing conclusions. Methods: Key informants reported differences in registration practice for capturing incidence date, death certificate case handling and registration of multiple primary tumours. Sensitivity analyses estimated their impact on one-year survival using baseline and supplementary cancer registration data from England and Sweden. Results: Variations in registration practice accounted for up to a 7.3 percentage point difference between unadjusted (estimates from previous ICBP survival data) and adjusted (estimates recalculated accounting for registration differences) one-year survival, depending on tumour site and jurisdiction. One-year survival estimates for four jurisdictions were affected by adjustment: New South Wales, Norway, Ontario, Sweden. Sweden and Ontario's survival reduced after adjustment, yet they remained the jurisdictions with the highest survival for breast and ovarian cancer respectively. Sweden had the highest unadjusted lung cancer survival of 43.6% which was adjusted to 39.0% leaving Victoria and Manitoba with the highest estimate at 42.7%. For colorectal cancer, Victoria's highest survival of 85.1% remained unchanged after adjustment. Conclusion: Population-based cancer survival comparisons can be subject to registration biases that may impact the reported 'survival gap’ between populations. Efforts should be made to apply consistent registration practices internationally. In the meantime, survival comparison studies should provide acknowledgement of or adjustment for the registration biases that may affect their conclusions.

AB - Background: International cancer survival comparisons use cancer registration data to report cancer survival, which informs the development of cancer policy and practice. Studies like the International Cancer Benchmarking Partnership (ICBP) have a duty to understand how registration differences impact on survival prior to drawing conclusions. Methods: Key informants reported differences in registration practice for capturing incidence date, death certificate case handling and registration of multiple primary tumours. Sensitivity analyses estimated their impact on one-year survival using baseline and supplementary cancer registration data from England and Sweden. Results: Variations in registration practice accounted for up to a 7.3 percentage point difference between unadjusted (estimates from previous ICBP survival data) and adjusted (estimates recalculated accounting for registration differences) one-year survival, depending on tumour site and jurisdiction. One-year survival estimates for four jurisdictions were affected by adjustment: New South Wales, Norway, Ontario, Sweden. Sweden and Ontario's survival reduced after adjustment, yet they remained the jurisdictions with the highest survival for breast and ovarian cancer respectively. Sweden had the highest unadjusted lung cancer survival of 43.6% which was adjusted to 39.0% leaving Victoria and Manitoba with the highest estimate at 42.7%. For colorectal cancer, Victoria's highest survival of 85.1% remained unchanged after adjustment. Conclusion: Population-based cancer survival comparisons can be subject to registration biases that may impact the reported 'survival gap’ between populations. Efforts should be made to apply consistent registration practices internationally. In the meantime, survival comparison studies should provide acknowledgement of or adjustment for the registration biases that may affect their conclusions.

KW - Cancer registration

KW - Cancer survival

KW - Date of diagnosis

KW - Death certificate

KW - International comparisons

KW - Multiple primaries

UR - http://www.scopus.com/inward/record.url?scp=85059598072&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2018.10.019

DO - 10.1016/j.canep.2018.10.019

M3 - Article

C2 - 30639877

AN - SCOPUS:85059598072

SN - 1877-7821

VL - 58

SP - 184

EP - 192

JO - Cancer Epidemiology

JF - Cancer Epidemiology

ER -

Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this